Next Article in Journal
Pulmonary Actinomycosis Complicated by Fistula of the Chest Wall
Previous Article in Journal
A Very Unusual Case of Interstitial Lung Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
ARM
Volume 89
Issue 5
10.5603/ARM.a2021.0072
arm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Nintedanib-Mediated Improvement in CT Imaging in Pulmonary Fibrosis Associated with Systemic Scleroderma

by
Kengo Nishino
,
Yuika Sasatani
,
Gen Ohara
,
Katsunori Kagohashi
and
Hiroaki Satoh
*
Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Japan
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2021, 89(5), 528-531; https://doi.org/10.5603/ARM.a2021.0072
Submission received: 16 January 2021 / Revised: 20 May 2021 / Accepted: 20 May 2021 / Published: 27 September 2021

Abstract

Nintedanib is an antifibrotic drug that has an inhibitory effect on growth factor tyrosine kinases. In patients with idiopathic pulmonary fibrosis and systemic scleroderma-associated interstitial pneumonia (SSc-IP), nintedanib has been effective in suppressing the decline in forced vital capacity over time and the onset of acute exacerbation of interstitial pneumonia. Here, we report a SSc-IP patient who showed an improvement on CT images following nintedanib treatment. To our knowledge, this is the first report of such a case. Although SSc-IP patients are very rare, additional clinical experience and understanding will be required to prove the therapeutic benefit of nintedanib in these cases in relation to improved chest images.
Keywords: systemic scleroderma; pulmonary fibrosis; nintedanib; computed tomography systemic scleroderma; pulmonary fibrosis; nintedanib; computed tomography

Share and Cite

MDPI and ACS Style

Nishino, K.; Sasatani, Y.; Ohara, G.; Kagohashi, K.; Satoh, H. Nintedanib-Mediated Improvement in CT Imaging in Pulmonary Fibrosis Associated with Systemic Scleroderma. Adv. Respir. Med. 2021, 89, 528-531. https://doi.org/10.5603/ARM.a2021.0072

AMA Style

Nishino K, Sasatani Y, Ohara G, Kagohashi K, Satoh H. Nintedanib-Mediated Improvement in CT Imaging in Pulmonary Fibrosis Associated with Systemic Scleroderma. Advances in Respiratory Medicine. 2021; 89(5):528-531. https://doi.org/10.5603/ARM.a2021.0072

Chicago/Turabian Style

Nishino, Kengo, Yuika Sasatani, Gen Ohara, Katsunori Kagohashi, and Hiroaki Satoh. 2021. "Nintedanib-Mediated Improvement in CT Imaging in Pulmonary Fibrosis Associated with Systemic Scleroderma" Advances in Respiratory Medicine 89, no. 5: 528-531. https://doi.org/10.5603/ARM.a2021.0072

Article Metrics

Back to TopTop